MCID: SCN007
MIFTS: 50

Secondary Hyperparathyroidism

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Secondary Hyperparathyroidism

MalaCards integrated aliases for Secondary Hyperparathyroidism:

Name: Secondary Hyperparathyroidism 12 36 15 17
Hyperparathyroidism, Secondary 44
Hyperparathyroidism Secondary 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12466
KEGG 36 H01669
MeSH 44 D006962
NCIt 50 C113335
SNOMED-CT 67 91478007
ICD10 32 E21.1
UMLS 70 C0020503

Summaries for Secondary Hyperparathyroidism

KEGG : 36 Secondary hyperparathyroidism (SHPT) is a chronic and progressive disorder characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism, mainly calcium and phosphorus. SHPT is generally caused by diffuse parathyroid hyperplasia in response to prolonged reduced levels of extracellular calcium from various secondary aetiologies. Although it is initially and adaptive response to a variety of stimuli resulting mainly in extracellular hypocalcaemia (vitamin D deficiency, chronic kidney disease, idiopathic hypercalciuria, calcium malabsorption), long-standing SHPT may eventually develop into autonomous HPT (ie, tertiary HPT). Because SHPT is a compensatory mechanism of the parathyroid glands, it commonly resolves with normalization of calcium and phosphorus homeostasis. After excluding reversible secondary aetiologies, first-line treatment of irreversible SHPT (often related to chronic kidney disease) mainly involves medical therapies.

MalaCards based summary : Secondary Hyperparathyroidism, also known as hyperparathyroidism, secondary, is related to vitamin d-dependent rickets and vitamin d-dependent rickets, type 2a. An important gene associated with Secondary Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers and Parathyroid hormone synthesis, secretion and action. The drugs Sevelamer and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and thyroid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Secondary hyperparathyroidism is the medical condition of excessive secretion of parathyroid hormone... more...

Related Diseases for Secondary Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism
Secondary Hyperparathyroidism Rare Hyperparathyroidism

Diseases related to Secondary Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 vitamin d-dependent rickets 32.1 VDR PTH CYP27B1 BGLAP
2 vitamin d-dependent rickets, type 2a 32.0 VDR CYP27B1
3 hyperphosphatemia 31.2 VDR PTH KL FGF23 CASR BGLAP
4 calcinosis 30.9 KL FGF23 CALCA
5 parathyroid adenoma 30.8 VDR PTH MEN1 CASR CALCA BGLAP
6 rickets 30.7 VDR PTH KL GC FGF23 CYP27B1
7 hypercalcemia, infantile, 1 30.7 VDR PTH CASR CALCA
8 multiple endocrine neoplasia, type i 30.7 PTH MEN1 CASR
9 parathyroid carcinoma 30.7 PTH MEN1 CASR CALCA
10 pseudohypoparathyroidism 30.7 PTH CALCA BGLAP
11 osteitis fibrosa 30.6 PTH FGF23 CASR CALCA BGLAP B2M
12 multiple endocrine neoplasia 30.6 PTH MEN1 CALCA
13 hypoparathyroidism 30.6 VDR PTH NR1I3 FGF23 CXADR CASR
14 calciphylaxis 30.6 VDR PTH FGF23 EPO CASR ALB
15 graves disease 1 30.6 PTH CALCA ALB
16 end stage renal disease 30.5 VDR PTH KL FGF23 EPO CASR
17 hypophosphatemic rickets, x-linked recessive 30.5 VDR FGF23 CYP27B1
18 osteomalacia 30.5 VDR PTH GC FGF23 CYP27B1 CASR
19 primary hyperparathyroidism 30.5 VDR PTH NR1I3 MEN1 KL GC
20 bone resorption disease 30.5 VDR TNFRSF11B PTH FGF23 CALCA BGLAP
21 renal osteodystrophy 30.5 VDR TNFRSF11B SLPI PTH FGF23 CASR
22 metabolic acidosis 30.5 PTH FGF23 BGLAP ALB
23 urolithiasis 30.4 VDR CASR ALB
24 hyperthyroidism 30.4 PTH CALCA BGLAP ALB ACP5
25 uremia 30.4 VDR TNFRSF11B PTH MEN1 EPO CASR
26 hyperparathyroidism 2 with jaw tumors 30.4 MEN1 CASR
27 idiopathic hypercalciuria 30.3 VDR SLPI NR1I3 CASR BGLAP
28 hypocalciuric hypercalcemia, familial, type i 30.3 PTH CASR
29 hypophosphatemia 30.3 VDR PTH KL FGF23 CYP27B1 BGLAP
30 thyroid gland medullary carcinoma 30.3 PTH MEN1 CALCA
31 hyperparathyroidism 30.2 VDR TNFRSF11B SLPI PTH NR1I3 MEN1
32 chronic pyelonephritis 30.2 CALCA B2M ALB
33 oncogenic osteomalacia 30.2 PTH FGF23
34 thyroid gland disease 30.2 PTH CALCA ALB
35 sclerosteosis 30.2 VDR PTH BGLAP
36 familial hypocalciuric hypercalcemia 30.1 VDR PTH MEN1 CXADR CASR CALCA
37 deficiency anemia 30.1 PTH FGF23 EPO B2M ALB
38 hyperparathyroidism, neonatal severe 30.1 NR1I3 CXADR CASR
39 spondyloarthropathy 1 30.1 TNFRSF11B PTH BGLAP
40 mammary paget's disease 30.1 TNFRSF11B PTH CALCA BGLAP ACP5
41 kidney disease 30.1 VDR TNFRSF11B SLPI PTH FGF23 EPO
42 mccune-albright syndrome 30.0 MEN1 FGF23 BGLAP
43 acute kidney failure 30.0 BMP7 B2M ALB
44 hyperostosis 30.0 TNFRSF11B KL FGF23
45 nephrolithiasis 29.9 VDR PTH MEN1 FGF23 CASR BGLAP
46 craniometaphyseal dysplasia, autosomal dominant 29.9 TNFRSF11B BGLAP ACP5
47 endemic goiter 29.8 PTH CALCA
48 taqi polymorphism 29.8 VDR TGFA
49 hypophosphatemic rickets, x-linked dominant 29.7 PTH KL FGF23 CYP27B1 BGLAP
50 osteochondrodysplasia 29.6 PTH FGF23 CALCA BGLAP ACP5

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism:



Diseases related to Secondary Hyperparathyroidism

Symptoms & Phenotypes for Secondary Hyperparathyroidism

GenomeRNAi Phenotypes related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.66 MEN1
2 Decreased viability GR00221-A-1 9.66 NR1I3 TNFRSF11B
3 Decreased viability GR00221-A-2 9.66 NR1I3 TNFRSF11B
4 Decreased viability GR00249-S 9.66 ACP5 ALB NR1I3 TNFRSF11B
5 Decreased viability GR00301-A 9.66 NR1I3 TGFA
6 Decreased viability GR00381-A-1 9.66 CALCA SLPI
7 Decreased viability GR00386-A-1 9.66 ALB B2M EPO KL NR1I3 VDR
8 Decreased viability GR00402-S-2 9.66 BMP7 CXADR TNFRSF11B

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ALB B2M BGLAP BMP7 CASR CXADR
2 cellular MP:0005384 10.35 ALB B2M BGLAP CASR CXADR CYP27B1
3 endocrine/exocrine gland MP:0005379 10.34 ALB B2M BGLAP BMP7 CASR CXADR
4 immune system MP:0005387 10.34 ALB B2M BGLAP BMP7 CASR CXADR
5 cardiovascular system MP:0005385 10.33 ALB B2M BMP7 CXADR EPO FGF23
6 hematopoietic system MP:0005397 10.29 B2M BGLAP BMP7 CASR CXADR CYP27B1
7 craniofacial MP:0005382 10.22 BMP7 CASR CXADR CYP27B1 KL MEN1
8 digestive/alimentary MP:0005381 10.21 ALB B2M BMP7 CASR CXADR FGF23
9 mortality/aging MP:0010768 10.17 ALB B2M BMP7 CASR CXADR EPO
10 integument MP:0010771 10.06 B2M BMP7 CASR CYP27B1 EPO FGF23
11 limbs/digits/tail MP:0005371 10.02 BMP7 CXADR CYP27B1 EPO FGF23 KL
12 muscle MP:0005369 9.86 ALB CASR CXADR EPO KL MEN1
13 renal/urinary system MP:0005367 9.81 ALB BMP7 CASR CXADR CYP27B1 FGF23
14 reproductive system MP:0005389 9.7 B2M BGLAP BMP7 CXADR CYP27B1 FGF23
15 skeleton MP:0005390 9.4 BGLAP BMP7 CASR CYP27B1 EPO FGF23

Drugs & Therapeutics for Secondary Hyperparathyroidism

Drugs for Secondary Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Calcium acetate Approved, Investigational Phase 4 62-54-4
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
8
Cinacalcet Approved Phase 4 226256-56-0 156419
9
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
12
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
13
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
14 Chelating Agents Phase 4
15 Vitamin D2 Phase 4
16 Ergocalciferols Phase 4
17 Hematinics Phase 4
18 Epoetin alfa Phase 4 113427-24-0
19 Liver Extracts Phase 4
20 Lipid Regulating Agents Phase 4
21 Anticholesteremic Agents Phase 4
22 Antimetabolites Phase 4
23 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
24 Hypolipidemic Agents Phase 4
25 Hormones Phase 4
26 Hormone Antagonists Phase 4
27 Calcium, Dietary Phase 4
28 Micronutrients Phase 4
29 Trace Elements Phase 4
30 Nutrients Phase 4
31 1 alpha-hydroxyergocalciferol Phase 4
32 Vitamins Phase 4
33 Calciferol Phase 4
34 Vasoconstrictor Agents Phase 4
35 Dihydroxycholecalciferols Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
Calcium carbonate Approved, Investigational Phase 3 471-34-1
38
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850
39
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 6433735 5283731
40
Maxacalcitol Investigational Phase 3 103909-75-7
41 Protective Agents Phase 3
42 Dermatologic Agents Phase 3
43 Pharmaceutical Solutions Phase 3
44 Hydroxycholecalciferols Phase 3
45 Phytosterol Phase 3
46 Gastrointestinal Agents Phase 2
47 Antacids Phase 2
48 Anti-Ulcer Agents Phase 2
49 ASP7991 Phase 2
50
Zoledronic Acid Approved Phase 1 118072-93-8 68740

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
3 A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT) Completed NCT03123406 Phase 4 Cinacalcet HCl
4 Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients Completed NCT01100723 Phase 4
5 Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
6 A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
7 A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
8 Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
9 Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients Completed NCT01101113 Phase 4 cinacalcet;control
10 A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
11 Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
12 Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
13 A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
14 Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
15 An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency Completed NCT03588884 Phase 4 Calcifediol Oral Capsule;Calcifediol Oral Product;Cholecalciferol;Paricalcitol Oral Capsule
16 A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
17 A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT). Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
18 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
19 A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis. Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
20 A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
21 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
22 A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
23 Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
24 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
25 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial Completed NCT03182699 Phase 4
26 A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
27 Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
28 The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
29 Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease Completed NCT00528788 Phase 4 doxercalciferol
30 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
31 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
32 A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management Completed NCT00431496 Phase 4 Cinacalcet
33 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
34 A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
35 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
36 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Completed NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
37 A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients Completed NCT01573520 Phase 4
38 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Suspended NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
39 Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Terminated NCT00664430 Phase 4 Calcitriol;Paricalcitol
40 Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis Terminated NCT00446329 Phase 4 cinacalcet
41 Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Terminated NCT00646282 Phase 4 doxercalciferol
42 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
43 The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction Terminated NCT00175149 Phase 4 Alfacalcidiol
44 Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial Unknown status NCT02536287 Phase 3
45 Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension. Unknown status NCT01479088 Phase 2, Phase 3 Cinacalcet HCl
46 The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism Completed NCT01191762 Phase 3 sevelamer carbonate;placebo
47 Calcium and Vitamin D Malnutrition in Elderly Women Completed NCT00352170 Phase 3
48 Phase 3 Study of SK-1403 ; Double-blinded Parallel Group in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Completed NCT03801980 Phase 3 SK-1403;Placebo
49 Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis) Completed NCT02549417 Phase 3 KHK7580
50 Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis) Completed NCT02549404 Phase 3 KHK7580

Search NIH Clinical Center for Secondary Hyperparathyroidism

Cochrane evidence based reviews: hyperparathyroidism, secondary

Genetic Tests for Secondary Hyperparathyroidism

Anatomical Context for Secondary Hyperparathyroidism

MalaCards organs/tissues related to Secondary Hyperparathyroidism:

40
Kidney, Bone, Thyroid, Skin, Spinal Cord, Breast, Prostate

Publications for Secondary Hyperparathyroidism

Articles related to Secondary Hyperparathyroidism:

(show top 50) (show all 6915)
# Title Authors PMID Year
1
The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. 61 54
20180772 2010
2
Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism. 54 61
20303786 2010
3
Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. 54 61
19839774 2010
4
Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. 61 54
20133492 2010
5
Physiology and pathophysiology of the calcium-sensing receptor in the kidney. 54 61
19923405 2010
6
FGF23-parathyroid interaction: implications in chronic kidney disease. 61 54
20010546 2010
7
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. 54 61
19890272 2010
8
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. 54 61
19965548 2010
9
Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease. 54 61
20091482 2010
10
The role of vitamin D receptor activation in chronic kidney disease. 54 61
20411052 2010
11
Clinical relevance of FGF-23 in chronic kidney disease. 54 61
19946326 2009
12
Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. 61 54
19371337 2009
13
The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients. 61 54
19640368 2009
14
Emerging topics in pediatric bone and mineral disorders 2008. 54 61
19615558 2009
15
Effects of calcimimetic on vascular calcification and atherosclerosis in uremic mice. 61 54
19303957 2009
16
Reduced relative lymphocyte count in african-americans with decompensated heart failure. 54 61
19174692 2009
17
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. 54 61
19050056 2009
18
Calcimimetics in the chronic kidney disease-mineral and bone disorder. 61 54
19363783 2009
19
Importance of vitamin D receptor activation in clinical practice. 61 54
19494616 2009
20
Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. 61 54
18839328 2009
21
Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period. 54 61
19194773 2009
22
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 54 61
19494617 2009
23
Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. 54 61
18515308 2008
24
Vitamin D receptor ligand therapy in chronic kidney disease. 54 61
18826852 2008
25
Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. 54 61
18579641 2008
26
[Altered calcium-phosphorus metabolism and low-protein diet]. 61 54
18828130 2008
27
Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. 61 54
18494747 2008
28
Endothelial dysfunction and chronic kidney disease: treatment options. 61 54
18729004 2008
29
Allosteric modulators of the human calcium-sensing receptor: structures, sites of action, and therapeutic potentials. 61 54
18782015 2008
30
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? 61 54
18322048 2008
31
Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. 61 54
18393827 2008
32
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. 61 54
18216315 2008
33
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. 54 61
18216322 2008
34
Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. 54 61
17854393 2008
35
(2S,2'R)-analogue of LG190178 is a major active isomer. 54 61
18054230 2008
36
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. 54 61
17914251 2008
37
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. 61 54
18178780 2008
38
[Basic and clinical aspects of calcimimetics. Calcimimetics and vascular calcification]. 54 61
18175878 2008
39
Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. 54 61
17652181 2007
40
Early lethality in Hyp mice with targeted deletion of Pth gene. 61 54
17615144 2007
41
Allosteric modulation of the calcium-sensing receptor. 61 54
19305800 2007
42
Vitamin D receptor: a highly versatile nuclear receptor. 61 54
17653231 2007
43
Vitamin D receptor agonists as anti-inflammatory agents. 61 54
20477154 2007
44
Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. 54 61
17635819 2007
45
Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. 61 54
17638802 2007
46
The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. 61 54
17200160 2007
47
The potential for vitamin D receptor activation in cardiovascular research. 54 61
17371189 2007
48
Incidence and risk factors of coronary artery disease in patients on chronic hemodialysis. 54 61
17417765 2007
49
Clinical lessons from the calcium-sensing receptor. 61 54
17237839 2007
50
Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients. 54 61
17275471 2007

Variations for Secondary Hyperparathyroidism

Expression for Secondary Hyperparathyroidism

Search GEO for disease gene expression data for Secondary Hyperparathyroidism.

Pathways for Secondary Hyperparathyroidism

GO Terms for Secondary Hyperparathyroidism

Cellular components related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNFRSF11B TGFA SLPI PTH KL GC
2 endoplasmic reticulum lumen GO:0005788 9.55 MEN1 FGF23 BGLAP B2M ALB
3 extracellular space GO:0005615 9.47 TNFRSF11B TGFA SLPI PTH KL GC

Biological processes related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 10.02 VDR NR1I3 MEN1 CALCA BMP7
2 response to drug GO:0042493 9.93 TNFRSF11B TGFA PTH BGLAP B2M
3 MAPK cascade GO:0000165 9.91 TGFA MEN1 KL FGF23
4 aging GO:0007568 9.88 KL EPO CALCA BGLAP
5 cellular calcium ion homeostasis GO:0006874 9.8 VDR PTH CASR CALCA
6 cellular protein metabolic process GO:0044267 9.8 MEN1 FGF23 CALCA B2M ALB
7 ossification GO:0001503 9.78 CASR BMP7 BGLAP ACP5
8 positive regulation of bone mineralization GO:0030501 9.72 PTH KL BMP7
9 calcium ion homeostasis GO:0055074 9.69 PTH KL CYP27B1
10 skeletal system development GO:0001501 9.65 VDR TNFRSF11B PTH BMP7 BGLAP
11 decidualization GO:0046697 9.63 VDR MEN1 CYP27B1
12 response to estrogen GO:0043627 9.62 TNFRSF11B EPO CYP27B1 BGLAP
13 response to inorganic substance GO:0010035 9.61 TNFRSF11B BGLAP
14 regulation of bone mineralization GO:0030500 9.61 FGF23 CYP27B1 BGLAP
15 response to magnesium ion GO:0032026 9.6 TNFRSF11B FGF23
16 response to fibroblast growth factor GO:0071774 9.59 PTH CASR
17 phosphate ion homeostasis GO:0055062 9.58 PTH FGF23
18 negative regulation of calcium ion transport into cytosol GO:0010523 9.57 EPO CALCA
19 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.56 KL FGF23
20 cellular response to vitamin D GO:0071305 9.54 FGF23 CASR BGLAP
21 vitamin D catabolic process GO:0042369 9.52 FGF23 CYP27B1
22 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.33 VDR FGF23 CYP27B1
23 response to vitamin D GO:0033280 9.26 PTH CYP27B1 BMP7 BGLAP
24 vitamin D metabolic process GO:0042359 8.92 VDR GC FGF23 CYP27B1

Molecular functions related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vitamin D binding GO:0005499 8.96 KL GC
2 hormone activity GO:0005179 8.92 PTH KL EPO CALCA

Sources for Secondary Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....